Introduction
Corneal transplantation is one of the most commonly performed allogenic transplant worldwide, with a consequently substantial shortage of donor corneal tissue.1
Different methods were developed to achieve the best possible preservation of cornea physiological properties in terms of corneal transparency, endothelial, epithelial and limbal stem cells viability, as well as the absence of microbiological contamination.2 3 Most of the tissue for corneal transplantation is processed by eye banks that can use either hypothermic storage (2–8°C up to 14 days) or storage under corneal culture or so-called ‘organ culture’ conditions (31–37°C up to 28 days). Both techniques have their own advantages and disadvantages.4 Organ culture allows a longer storage period. However, due to the absence of a deswelling agent in the storage media, it leads to corneal swelling that needs to be reversed before transplantation and requires more expertise and additional instruments, making it a relatively complicated technique. Hypothermic storage allows a shorter storage time of up to 14 days, corneal quality evaluations are performed only before the storage, but this method is easier to implement in practice. Most importantly, the limited evidence suggests similar graft survival and functional state independent of the storage method used, even if only a few studies performed a direct comparison.4 Nowadays, hypothermic corneal storage is used by most in the USA, while organ culture is more prevalent in Europe.5
Current guidelines,6 7 independently of the storage method, prioritise the maintenance of corneal and in particular endothelial, quality and safety. Maintaining the physiological features of preserved human corneas before transplantation is critical not only for eye bank technicians, clinicians and scientists, but also for manufacturers of corneal storage media. Even though the surgeon plays a pivotal role in assessing the suitability of the tissue for transplantation, all personnel involved in cornea processing share responsibility for achieving a successful outcome. In particular, as pointed out by the new EU 2017/745 Medical Device Regulation (MDR),8 the manufacturer is requested to ensure the safety and performance of its medical devices, by eliminating or reducing risks for safety as far as possible, through safe design and manufacture, with suitable verification and validation tests.9 10
The hypothermic storage medium ‘Corneal Chamber’ (AL.CHI.MI.A. S.R.L, Italy) has been developed for hypothermic cornea storage medical device for cornea preservation at 2–8°C for up to 14 days. Corneal Chamber medium (CCM) contains several components, including dextran, nutrients and energetic sources, that aimed to preserve donor tissue until transfer to the corneal culture medium, as well as gentamicin sulfate. The high bacterial contamination rates of donor cornea during all preservation phases despite the povidone–iodine decontamination procedure11 suggest a potential benefit of gentamicin sulfate presence in the storage medium because it maintains antimicrobial activity even at low temperatures,12 and further increases its effectiveness during warming to room temperature (RT) before use for transplantation.13 All these components, including gentamicin sulfate, shall be removed before transplantation and the phosphate-buffered saline solution for corneal rinsing (PSS-L, AL.CHI.MI.A. S.R.L., Italy) was developed for this purpose. PSS-L is a Conformité Européenne (CE)-marked medical device that has undergone rigorous testing and evaluation to ensure the product safety and efficacy for its specific applications (eg, donor globe and corneal rinsing). In particular, lot-to-lot uniformity is guaranteed by means of stringent control of the industrial processes, accompanied by quality control testing of both raw materials and industrial batches.
The present study aimed to evaluate whether after hypothermic storage in CCM followed by PSS-L rinsing, the human cornea is suitable for transplantation and no residues of the storage medium remain in the tissue. Due to the scarce availability of human corneas for research purposes, porcine corneas were also included in the study, according to a recently developed model that accurately predicts the response to storage conditions and treatments of human corneas.14 Quality parameters of human and porcine corneas at the beginning (Day 0) and after 14±1 days (Day 14) of hypothermic storage in CCM were evaluated, including endothelial cell density (ECD), percentage of hexagonal cells (HEX%), coefficient of variation in cell area (CV%), endothelial mortality (%) and corneal transparency. The abovementioned corneal quality parameters were also evaluated following rinsing with PSS-L (Day 14PR; PR: post rinsing) at the end of storage. To verify that no antimicrobial remained in the corneal tissue after PSS-L rinse, the content of gentamicin sulfate in human corneal homogenates was measured by ultra-high performance liquid chromatography (UHPLC). The results of the performed study give information about the safety and performance of the medical devices already used in clinical settings. Moreover, the study provides new information about the previously developed and optimised animal model14 for evaluating the efficacy of corneal storage methods.